SPRINT: Phase II study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).
2018 ◽
Vol 36
(15_suppl)
◽
pp. 10503-10503
◽
Keyword(s):
Phase Ii
◽
2016 ◽
Vol 34
(15_suppl)
◽
pp. 11053-11053
◽